Compare CVE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | ILMN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0B | 37.0B |
| IPO Year | 2009 | 2000 |
| Metric | CVE | ILMN |
|---|---|---|
| Price | $28.17 | $198.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | $37.67 | ★ $261.45 |
| AVG Volume (30 Days) | ★ 6.4M | 2.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 3.65 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $39.82 | $6.61 |
| Revenue Next Year | N/A | $7.00 |
| P/E Ratio | ★ $18.07 | $57.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.63 | $112.65 |
| 52 Week High | $34.16 | $309.35 |
| Indicator | CVE | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 32.66 |
| Support Level | $27.34 | $182.76 |
| Resistance Level | $30.57 | $201.83 |
| Average True Range (ATR) | 0.92 | 13.28 |
| MACD | -0.19 | -4.90 |
| Stochastic Oscillator | 23.40 | 1.65 |
Cenovus Energy Inc is a Canadian integrated energy group. The group's upstream operations include oil sands projects in northern Alberta; thermal and conventional crude oil, natural gas, and natural gas liquids (NGLs) projects across Western Canada; crude oil production offshore Newfoundland and Labrador; and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada. The group's reportable segments are: Oil Sands, Conventional, Offshore, Canadian Refining, U.S Refining, and Corporate and Eliminations. Maximum revenue is generated from its Oil Sands segment. Geographically, the group derives maximum revenue from the U.S., followed by Canada and China.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.